Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

February 2011

Clinical Trials, Cohort Studies, Pilot Studies

Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C. Cheung O, Sterling RK, Salvatori J, et al. J Clin Gastroenterol. 2011 Jan;45(1):          76-82.

http://www.ncbi.nlm.nih.gov/pubmed/20818236

Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. Chayama K, Hayes CN, Yoshioka K, et al. J Gastro-enterol. 2011 Jan 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21246384

Clinical Significance of Perihepatic Lymphadenopathy in Patients with Chronic Hepatitis C Infection. Tavakoli-Tabasi S, Ninan S. Dig Dis Sci. 2011 Jan 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21259074

Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. Trapero-Marugán M, Mendoza J, Chaparro M, et al. World J Gastroenterol. 2011 Jan 28;17(4):493-8.

http://www.ncbi.nlm.nih.gov/pubmed/21274379

Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C. Manns M, Zeuzem S, Sood A, et al. J Hepatol. 2011 Jan 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21237227

U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for "Difficult-to-Treat" HCV Genotype 1 Patients. Ho SB, Aqel B, Dieperink E, Liu S, et al. Dig Dis Sci. 2011 Jan 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21221804

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Lawitz E, Godofsky E, Rouzier R, et al. Antiviral Res. 2011 Jan 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21255610

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Thompson AJ, Santoro R, Piazzolla V, et al. Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10.

http://www.ncbi.nlm.nih.gov/pubmed/21274861

Basic and Applied Science, Pre-Clinical Studies

Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. Ryan MC, Desmond PV, Slavin JL, Congiu M. J Viral Hepat. 2011 Jan;18(1):53-60. doi: 10.1111/j.1365-2893.2010.01283.x.

http://www.ncbi.nlm.nih.gov/pubmed/20196803

A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease. Washburn ML, Bility MT, Zhang L, et al. Gastroenterology. 2011 Jan 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21237170

The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families. Murakami Y, Toyoda H, Tanaka M, et al. PLoS One. 2011 Jan 24;6(1):e16081.

http://www.ncbi.nlm.nih.gov/pubmed/21283674

Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol.

Teissier E, Zandomeneghi G, Loquet A, et al. PLoS One. 2011 Jan 25;6(1):e15874.

http://www.ncbi.nlm.nih.gov/pubmed/21283579

Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection. Budkowska A, Kakkanas A, Nerrienet E, et al. PLoS One. 2011 Jan 6;6(1):e15871.

http://www.ncbi.nlm.nih.gov/pubmed/21283512

Extracellular hepatitis C virus core protein activates STAT3 in human onocyte/ macrophage/dendritic cells via an IL-6 autocrine pathway. Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS. J Biol Chem. 2011 Jan 31. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21282107

HIV/HCV Coinfection

Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients.

Macías J, Mira J, Gilabert I, et al. HIV Med. 2011 Jan;12(1):14-21. doi: 10.1111/j.1468-1293.2010.00836.x.

http://www.ncbi.nlm.nih.gov/pubmed/20497249

Hepatitis C virus treatment rates and outcomes in HIV/hepatitis C virus co-infected individuals at an urban HIV clinic. Murray MC, Barrios R, Zhang W, et al. Eur J Gastroenterol Hepatol. 2011 Jan;23(1):45-50.

http://www.ncbi.nlm.nih.gov/pubmed/21139470

Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease. Berzsenyi MD, Woollard DJ, McLean CA, et al. J Hepatol. 2011 Jan 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21266183

HCV-Specific T cell Responses in HIV/HCV coinfected patients on HAART are comparable to those observed in HCV-monoinfected individuals. Rallón NI, Soriano V, Restrepo C, et al. J Acquir Immune Defic Syndr. 2011 Jan 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21283015

Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. Blanco F, Barreiro P, Ryan P, et al. J Viral Hepat. 2011 Jan;18(1):11-6. doi: 10.1111/j.1365-2893.2009.01261.x.

http://www.ncbi.nlm.nih.gov/pubmed/20088890

Comparison of HIV-, HBV-, HCV- and Co-Infection Prevalence between Chinese and Burmese Intravenous Drug Users of the China-Myanmar Border Region. Zhou YH, Liu FL, Yao ZH, Duo L, Li H, Sun Y, Zheng YT. PLoS One. 2011 Jan 21;6(1):e16349.

http://www.ncbi.nlm.nih.gov/pubmed/21283696

Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C. Matthews GV, Pham ST, Hellard M, et al. Clin Infect Dis. 2011 Jan 31. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21282185

Incident Hepatitis C Virus Infection among US HIV-Infected Men Enrolled in Clinical Trials. Taylor LE, Holubar M, Wu K, et al. Clin Infect Dis. 2011 Jan 31. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21282184

HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia. Diong C, Raboud J, Li M, Cooper C; the Ontario HIV Treatment Network Cohort Study Team. HIV Med. 2011 Jan 18. doi: 10.1111/j.1468-1293.2010.00897.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21244600

Complementary and Alternative Medicine

In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus. Javed T, Ashfaq UA, Riaz S, Rehman S, Riazuddin S. Virol J. 2011 Jan 19;8(1):26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21247464

Epidemiology, Diagnostics, and Miscellaneous Works

Prevalence of hepatitis B virus and hepatitis C virus among blood donors at a tertiary care hospital in India: a five-year study. Meena M, Jindal T, Hazarika A. Transfusion. 2011 Jan;51(1):198-202. doi: 10.1111/j.1537-2995.2010.02801.x.

http://www.ncbi.nlm.nih.gov/pubmed/20663107

Vietnamese community screening for hepatitis B virus and hepatitis C virus. Kallman JB, Tran S, Arsalla A, et al. J Viral Hepat. 2011 Jan;18(1):70-6. doi: 10.1111/j.1365-2893.2010.01278.x.

http://www.ncbi.nlm.nih.gov/pubmed/20196807

Needle exchange as a safe haven in an unsafe world. MacNeil J, Pauly B. Drug Alcohol Rev. 2011 Jan;30(1):26-32. doi: 10.1111/j.1465-3362.2010.00188.x.

http://www.ncbi.nlm.nih.gov/pubmed/21219494

Changes in Blood-borne Infection Risk Among Injection Drug Users. Mehta SH, Astemborski J, Kirk GD, et al. J Infect Dis. 2011 Mar;203(5):587-94. Epub 2011 Jan 31.

http://www.ncbi.nlm.nih.gov/pubmed/21282191

Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates).

Almasio PL, Babudieri S, Barbarini G, et al. Dig Liver Dis. 2011 Jan 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21256097

The Role of Patient Religiosity in the Evaluation and Treatment Outcomes for Chronic HCV Infection. Raghavan R, Ferlic-Stark L, Clarke C, Rungta M, Goodgame R. J Relig Health. 2011 Jan 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21246281

Liver Cancer

Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Cho LY, Yang JJ, Ko KP, et al. Int J Cancer. 2011 Jan 1;128(1):176-84. doi: 10.1002/ijc.25321.

http://www.ncbi.nlm.nih.gov/pubmed/20232388

Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer.

McGivern DR, Lemon SM. Oncogene. 2011 Jan 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21258404

Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. El-Serag HB, Kramer JR, Chen GJ, et al. Gut. 2011 Jan 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21257990

Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Morgan TR. Recent Results Cancer Res. 2011;188:85-99.

http://www.ncbi.nlm.nih.gov/pubmed/21253791

Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Davila JA, Henderson L, Kramer JR, et al. Ann Intern Med. 2011 Jan 18;154(2):85-93.

http://www.ncbi.nlm.nih.gov/pubmed/21242365

A Comparison of Prognosis between Patients with Hepatitis B and C Virus-related Hepatocellular Carcinoma Undergoing Resection Surgery. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. World J Surg. 2011 Jan 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/21207029